Clinical Trial · NCT05622240

99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer

Overview

This is an open-label single photon emission tomography/computed tomography (SPECT/CT) study to investigate the imaging performance of 99mTc-MIRC213 in breast cancer patients. A single dose of 11.1-14.8Mega-Becquerel (MBq) per kilogram body weight 99mTc-MIRC213 will be injected intravenously. Visual and semiquantitative method will be used to assess the SPECT/CT images.

Sponsor

Peking Union Medical College Hospital

Phase

Early Phase 1

Contacts

Zhaohui Zhu, Dr (CONTACT)

pumch_jacobwong@163.com

+8619800370331

Rongxi Wang, Dr (CONTACT)

zhzwrx.123@163.com

+8615584172170

Zhaohui Zhu, Dr (STUDY_CHAIR)

ClinicalTrials.gov

NCT05622240

Drug / Compound

MIRC213

Isotope(s):

Target(s):

HER2

Ligand Class: Small Proteins and Antibody Fragments

Eligibility

Inclusion

Inclusion criteria not yet provided.

Exclusion

The exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study, and undergoing any preceding local or systemic therapies that might interfere with HER2 binding.